Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9056116 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US9029355 | MARINUS | Solid ganaxolone compositions and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US8618087 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US8367651 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US7858609 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US8022054 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US8318714 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US10603308 | MARINUS | Methods and compositions for treatment of epileptic disorders |
Aug, 2037
(13 years from now) |
Ztalmy is owned by Marinus.
Ztalmy contains Ganaxolone.
Ztalmy has a total of 8 drug patents out of which 0 drug patents have expired.
Ztalmy was authorised for market use on 01 June, 2022.
Ztalmy is available in suspension;oral dosage forms.
Ztalmy can be used as treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older.
Drug patent challenges can be filed against Ztalmy from 01 June, 2026.
The generics of Ztalmy are possible to be released after 10 August, 2037.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 01, 2027 |
Orphan Drug Exclusivity(ODE-395) | Jun 01, 2029 |
Drugs and Companies using GANAXOLONE ingredient
NCE-1 date: 01 June, 2026
Market Authorisation Date: 01 June, 2022
Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older
Dosage: SUSPENSION;ORAL